Sanofi SA is close to a deal to take over U.S. drug maker Bioverativ Inc for more than $11.5 billion, the Wall Street Journal reported, citing people familiar with the matter. The potential deal, which could be announced as soon as Monday, would value Bioverativ at about $105 a share, the Journal reported. The price represents a 64 percent premium to Bioverativ stock's close on Friday on the Nasdaq.
Investors shrugged off the threat last week, saying they were not worried about a major pullback in shares if U.S. lawmakers failed to strike a deal. "These things have no near-term or midterm economic impact whatsoever," said Michael Purves, chief global strategist and head of derivatives strategy for Weeden & Co in New York. "They are kind of embarrassing for the United States, but it's not really going to alter business or consumer confidence," he said.
Steve Okun of McLarty Associates says it is 'very clear' the Republicans don't yet know who will take the blame for the government shutdown.
Craig Zeng of LexinFintech Holdings says that regulations on micro-lending in China follow innovations by fintech players and are welcome.
The Latest on the government shutdown (all times local): 9:30 p.m. The government shutdown will continue into Monday. The Senate will vote at noon on Monday on whether to cut off a Democratic filibuster ...
Paul Gruenwald of S&P Global says that resolving the U.S. government funding standoff may require more pressure to bring the parties to compromise.
Confidence among Japanese manufacturers jumped in January to an 11-year high, the Reuters Tankan poll showed on Monday, highlighting corporate optimism driven by nearly two years of uninterrupted economic ...
